Key result
Combination therapy using bosentan with prostanoids or PDE-5 inhibitors improves exercise capacity in patients with pulmonary arterial hypertension compared with placebo.
Why the study?
Does combination therapy improve exercise capacity and long-term outcomes in patients with pulmonary arterial hypertension?
Does combination therapy improve exercise capacity and long-term outcomes in patients with pulmonary arterial hypertension?
Combination therapy in pulmonary arterial hypertension appears to improve exercise capacity and may provide acceptable long-term results in advanced disease.
Answers are grounded in this paper and cite their sources.
May support bosentan combinations for exercise capacity in PAH; leaves open long-term outcome benefits and optimal regimens.
There is a strong clinical rationale for combination therapy in pulmonary arterial hypertension (PAH), as several pathological pathways have been implicated in its pathogenesis and no single agent has yet been shown to deliver completely satisfactory results. Registry data indicate that use of combination therapy is in fact common in existing clinical practice, even though support has been largely empirical or derived from small-scale observational studies. Data from large, adequately powered, randomised controlled trials of combination therapy in PAH are now emerging and suggest that combination therapy may be clinically beneficial. Studies of bosentan in combination with prostanoids and phosphodiesterase (PDE)-5 inhibitors show consistent evidence of improvements in exercise capacity compared with placebo. Similar improvements have been observed with PDE-5 inhibitors in combination with prostanoids. The appropriate timing of combination therapy requires further evaluation but goal-oriented therapy using combinations of oral and inhaled drugs has been shown to provide acceptable long-term results in patients with advanced PAH. Monitoring should be performed regularly and be based on repeatable, noninvasive, measurable parameters that have prognostic value.
No takes yet. Share an insight, caveat, or question.
Galiè et al. (2009) conducted a review in Pulmonary arterial hypertension (PAH). Combination therapy (e.g., bosentan with prostanoids and PDE-5 inhibitors) vs. Placebo was evaluated on Exercise capacity. Combination therapy using bosentan with prostanoids or PDE-5 inhibitors improves exercise capacity in patients with pulmonary arterial hypertension compared with placebo.
Synapse has enriched 10 related papers. Consider them for comparative context: